Yatharth Q1FY27: consolidated PAT +8% YoY as margins compress despite 51% revenue surge
PAT +8.05% YoY · revenue +51.47% · margins compressing · miss vs street
₹392.65 Cr
+51.47% YoY
₹45.42 Cr
+8.05% YoY
11.44%
-4.3pp YoY
₹4.88
Yatharth Hospital's consolidated Q1 FY27 revenue rose 51.5% YoY (14.96% QoQ) to Rs392.7 Cr, comfortably ahead of management's own FY27 guidance to "surpass" FY26's 36% YoY growth, and above the Rs314 Cr Street estimate from Uniresearch/Univest. Consolidated PAT of Rs45.4 Cr grew just 8.0% YoY (1.6% QoQ) and came in well below the Street's Rs59 Cr PAT estimate −a clear miss on the bottom line even as revenue beat. No exceptional items feature in either period, so the 8% YoY PAT growth is a clean, unadjusted number, not distorted by one-offs.
Q1 FY-2027 vs prior quarters
The gap between revenue and profit growth traces to margin compression across both operating and financing lines. Consolidated OPM (EBITDA margin) fell to 23.35% from 25.02% a year ago −slipping below management's guided 24-25% band that was reaffirmed just last quarter −while NPM dropped more sharply to 11.44% from 15.74% YoY (and from 12.82% last quarter). Finance costs jumped roughly 34x YoY to Rs6.59 Cr and depreciation rose 89% to Rs28.24 Cr, both consequences of debt-funded capacity additions, including the Rs100 Cr acquisition of an under-construction 250-bed Gurugram hospital completed June 12, 2026. Employee costs also grew 61.7% YoY to Rs77.91 Cr as the company staffed up ahead of ramp-up.
The stock went into the print at ₹898.75, up 8.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Yatharth Hospitals provided strong guidance for FY27, expecting to surpass the 36% YoY revenue growth achieved in FY26. They also maintained their consolidated EBITDA margin guidance of 24-25% and anticipate further improvements. The company is confident in its cluster-based expansion strategy, aiming to reach 5,000 be
— This quarter: missed
Standalone PAT grew only 3.9% YoY to Rs28.17 Cr, versus consolidated's 8.0%, confirming that most of the incremental profit and nearly all of the revenue growth is coming from subsidiaries and newer hospital assets rather than the core standalone entity. Consolidated PAT attributable to owners was Rs47.06 Cr (EPS Rs4.88, +12.2% YoY), higher than total group PAT of Rs45.42 Cr because non-controlling interests posted a Rs1.64 Cr loss for the quarter −a detail worth noting when reconciling the two profit figures. Alongside results, the board declared a first interim FY27 dividend of Rs0.50/share (record date August 14, 2026) and approved a new employee stock option scheme covering 2.5 lakh shares, both signalling confidence even as near-term margins soften. No separate management press release was available in the record for this quarter.
W1
Whether OPM recovers toward management's guided 24-25% EBITDA margin band after slipping to 23.35% this quarter
W2
Ramp-up trajectory and margin contribution of the newly acquired 250-bed Gurugram hospital (Rs100 Cr, construction-stage, commercial ops targeted within 12 months)
W3
Finance-cost trend as debt-funded cluster expansion (targeting 5,000 beds, ~70% via acquisitions) continues −costs already up ~34x YoY this quarter
Figures converted from INR Millions (filing) to Crore, /10. Consolidated profitAfterTax (Rs45.42 Cr) is total group PAT before NCI split, matching our DB's quarterly-consolidated basis; PAT attributable to owners was Rs47.06 Cr (basic EPS Rs4.88) because non-controlling interests posted a Rs1.64 Cr loss this quarter. No exceptional items in either period. Prior-period comparatives in this filing are regrouped/reclassified per company note 6/7, causing minor variance vs previously recorded June-2025 figures.
Informational and educational content only. Not investment advice.